On March 7, Gelonghui | Xintian Pharmaceutical (002873.SZ) announced that it plans to purchase 85.12% of Huilun Pharmaceutical's shares held by 88 Huilun Pharmaceutical shareholders, including Dong Dalun, Dong Zhu, and Hainan Qianyao, through the issuance of shares. After the transaction is completed, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company. This transaction does not involve raising supporting funds. After the audit and evaluation work relating to the underlying asset is completed, the listed company will sign a supplementary agreement with the counterparty to issue shares and purchase assets, confirm the final transaction price and transaction plan, and disclose it in the restructuring report.
Huilun Pharmaceutical's main business is R&D, production and sales of small molecule chemicals. It is committed to innovation and development in the fields of immuno-inflammatory, anti-tumor, cardiovascular, gynecologic, and andrology diseases. Huilun Pharmaceutical focuses on unmet clinical needs, lays out chemicals through source innovation, improved innovation, and high-end generics, and is committed to providing patients with safe, effective and economical treatment options.